PF-Atlas › Clinical Trials › NCT00662714
Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis
Repaglinide · Phase 3
Registry ID
NCT00662714
Phase
Phase 3
Status
Completed
Drug / intervention
Repaglinide
Sponsor
Mukoviszidose Institut gGmbH
Start
2001-09
About this trial
Repaglinide is evaluated in NCT00662714, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Mukoviszidose Institut gGmbH. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00662714 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.